Publicacions en col·laboració amb investigadors/es de Harvard University (17)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2023

  1. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome

    Biomedicine and Pharmacotherapy, Vol. 161

  2. Corrigendum: Role of NAFLD on the health related QoL response to lifestyle in patients with metabolic syndrome: The PREDIMED plus cohort(Front. Endocrinol., (2022), 13, (868795), 10.3389/fendo.2022.868795)

    Frontiers in Endocrinology

  3. Dietary Iron, Anemia Markers, Cognition, and Quality of Life in Older Community-Dwelling Subjects at High Cardiovascular Risk

    Nutrients, Vol. 15, Núm. 20

  4. Estimation of fatty liver disease clinical role on glucose metabolic remodelling phenotypes and T2DM onset

    European Journal of Clinical Investigation, Vol. 53, Núm. 10

2022

  1. Morbid liver manifestations are intrinsically bound to metabolic syndrome and nutrient intake based on a machine-learning cluster analysis

    Frontiers in Endocrinology, Vol. 13

  2. Role of NAFLD on the Health Related QoL Response to Lifestyle in Patients With Metabolic Syndrome: The PREDIMED Plus Cohort

    Frontiers in Endocrinology, Vol. 13

2021

  1. A Mediterranean lifestyle reduces the risk of cardiovascular disease in the “Seguimiento Universidad de Navarra” (SUN) cohort

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 31, Núm. 6, pp. 1728-1737

  2. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial

    EClinicalMedicine, Vol. 32

2020

  1. Mortality prediction in chronic obstructive pulmonary disease comparing the gold 2015 and gold 2019 staging: A pooled analysis of individual patient data

    ERJ Open Research, Vol. 6, Núm. 4, pp. 1-10

2019

  1. External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study

    COPD: Journal of Chronic Obstructive Pulmonary Disease

2016

  1. Prognostic assessment in COPD without lung function: The B-AE-D indices

    European Respiratory Journal, Vol. 47, Núm. 6, pp. 1635-1644

2015

  1. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: A pooled analysis of individual patient data

    The Lancet Respiratory Medicine, Vol. 3, Núm. 6, pp. 443-450

2014

  1. Finding the best thresholds of FEV1and dyspnea to predict 5-year survival in COPD patients: The COCOMICS study

    PLoS ONE, Vol. 9, Núm. 2

2013

  1. Distribution and prognostic validity of the new global initiative for chronic obstructive lung disease grading classification

    Chest, Vol. 143, Núm. 3, pp. 694-702

  2. Multicomponent indices to predict survival in COPD: The COCOMICS study

    European Respiratory Journal, Vol. 42, Núm. 2, pp. 323-332